Formulary
Mirabegron: Indications, Dosing, Side Effects and Interactions
Mirabegron clinical drug profile including indications, dosing, side effects, cautions and interactions.
MedNext Academy | 3 min read
Mirabegron: Indications, Dosing, Side Effects and Interactions
Mirabegron clinical drug profile including indications, dosing, side effects, cautions and interactions.
Indications and dose
**Urinary frequency, urgency, and urge incontinence**
- **Adult** (By Mouth): 50 mg once daily.
Cautions
History of QT-interval prolongation; stage 2 hypertension
Contraindications
Severe uncontrolled hypertension (systolic blood pressure 180 mmHg or diastolic blood pressure 110 mmHg)
Side effects
Common or very common Arrhythmias; constipation; diarrhoea; dizziness; headache; increased risk of infection; nausea Uncommon Cystitis; dyspepsia; gastritis; joint swelling; palpitations; skin reactions; vulvovaginal pruritus Rare or very rare Angioedema; eyelid oedema; hypersensitivity vasculitis; hypertensive crisis; lip swelling; urinary retention Frequency not known Insomnia
Interactions
**Severe interactions:**
- Mirabegron is not recommended in patients with severe renal impairment (eGFR 15 to 29 ml/min/1.73 m 2 ) or patients with moderate hepatic impairment (ChildPugh Class B) concomitantly receiving...
- Caution is advised if mirabegron is co-administered with medicinal products with a narrow therapeutic index and significantly metabolised by CYP2D6, such as thioridazine, Type 1C antiarrhythmics...
**Other interactions (24):**
- In vitro data Mirabegron is transported and metabolised through multiple pathways.
- Mirabegron is a substrate for cytochrome P450 (CYP) 3A4, CYP2D6, butyrylcholinesterase, uridine diphosphoglucuronosyltransferases (UGT), the efflux transporter P-glycoprotein (Pgp) and the influx...
- Studies of mirabegron using human liver microsomes and recombinant human CYP enzymes showed that mirabegron is a moderate and time-dependent inhibitor of CYP2D6 and a weak inhibitor of CYP3A.
- Mirabegron inhibited Pgpmediated drug transport at high concentrations.
- In vivo data Drug-drug interactions The effect of co-administered medicinal products on the pharmacokinetics of mirabegron and the effect of mirabegron on the pharmacokinetics of other medicinal...
- Most drugdrug interactions were studied using a dose of 100 mg mirabegron given as oral controlled absorption system (OCAS) tablets.
Pregnancy
Avoid-toxicity in animal studies.
Breast feeding
Avoid-present in milk in animal studies.
Hepatic impairment
Manufacturer advises caution in moderate impairment (risk of increased exposure); avoid in severe impairment (no information available). Dose adjustments Manufacturer advises dose reduction to 25 mg once daily in moderate impairment.
Renal impairment
Avoid if eGFR less than 15 mL/minute/1.73 m 2 (no information available). M Dose adjustments Reduce dose to 25 mg once daily if eGFR 15-29 mL/minute/1.73 m 2 . M See Prescribing in renal impairment .
Medicinal forms
Clinical governance
**Author:** MedNext Clinical Team. **Clinical reviewer:** Dr Shameer Deen, MBBS, MS, MRCS. **Sources:** BNF, Indian Pharmacopoeia, CIMS India. **Correction:** Report errors at support@mednext.academy.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- Growing visual cheat sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Subject HubPharmacology Hub
All pharmacology resources in one place.
Drug SchedulesIndian Drug Schedules
Schedule H, H1, X and G classifications.
FormularyBrowse all drugs
Search 1,850+ drug profiles.
Study Mirabegron in the MedNext app
Challenge yourself with targeted pharmacology MCQs on this drug class. Every explanation links back to the chapter that teaches the concept.
Start drug challengeExplore the full formulary

